* Cue Biopharma Inc CUE.OQ reported a quarterly adjusted
loss
of 29 cents per share for the quarter ended in June. The mean
expectation of four analysts for the quarter was for a loss
of 30 cents per share.
* Revenue rose 5,215.4% to $1.38 million from a year ago;
analysts
expected $907.50 thousand.
* Cue Biopharma Inc's reported EPS for the quarter was a
loss
of 29 cents.
* The mean earnings estimate of analysts had risen by
about 3.2%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
* Cue Biopharma Inc shares had fallen by 1.9% this
quarter and
gained 25.6% so far this year.
* The company reported a quarterly loss of $13.19 million.
* Wall Street's median 12-month price target for Cue
Biopharma Inc
is $9.00
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
This summary was machine generated from LSEG Refinitiv data
August 9 at 09:03 p.m. UTC. All figures in US dollars unless
otherwise stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2023 -0.30 -0.29 Beat
Mar. 31 2023 -0.29 -0.29 Met
Dec. 31 2022 -0.31 -0.38 Missed
Sep. 30 2022 -0.38 -0.31 Beat